problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl201056543-51problendo-4752Research ArticleСтатьиArticlesЗначение комплексного контроля гликемии при сахарном диабете 2-го типаThe importance of combined glycemic control in patients with type 2 diabetes mellitusKononenkoI Vshakhtarina@bk.ruSmirnovaO M-201015102010565ТОМ 56, №5 (2010)4351Copyright © Kononenko I.V., Smirnova O.M., 20102010Kononenko I.V., Smirnova O.M.Kononenko I.V., Smirnova O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/4752

Снижение риска развития микрососудистых осложнений при интенсивном контроле гликемии является доказанным, тогда как вопрос о его влиянии на макрососудистые осложнения не решен и продолжает обсуждаться. Учитывая, что основным патогенетическим фактором и пусковым моментом, лежащим в основе осложнений сахарного диабета (СД), является гипергликемия, необходимо четко определить на какие показатели углеводного обмена следует ориентироваться при выборе тактики терапии и установить их целевые значения. Контроль уровня HbA1c - наиболее доступный и информативный способ оценки длительной компенсации СД 2-го типа. Однако данный тест имеет некоторые ограничения, которые могут влиять на его клиническое использование. Исследование только ГПН не отражает полностью качество лечения СД 2-го типа. Существует потенциальная взаимосвязь между высоким уровнем ППГ и развитием сосудистых осложнений. Показано, что вариабельность уровня глюкозы может быть важным фактором риска развития осложнений СД. Полный диапазон измерений параметров гликемии, включая уровень глюкозы в плазме крови натощак, уровень HbA1c и уровень глюкозы после еды может обеспечить представление об общей картине заболевания при выборе лечения.

The contribution of intensive control of glycemia to the reduction of the risk of microvascular complications of type 2 diabetes mellitus is known perfectly well whereas its influence on the development of macrovascular complications remains to be clarified and remains a subject of debates. Bearing in mind that hyperglycemia is a key pathogenetic factor triggering formation of diabetic complications, it is necessary to identify characteristics of carbohydrate metabolism to be taken into account when choosing therapeutic strategies and to determine their target values. Control of the HbA1c level remains the most accessible and informative tool for the assessment of the efficiency of long-term compensation of type 2 diabetes mellitus. However, this method is not altogether free from limitations that can hamper its clinical application. The fasting glycemia level does not completely reflect the quality of DM2 treatment. There is potential relationship between high postprandial plasma glucose levels and the development of vascular complications. Also, it has been shown that variability of glucose concentration may be an important risk factor of diabetic complications. Measurement of the full range of glycemic parameters including fasting plasma glucose level, HbA1c and postprandial glycemia gives an idea of the general picture of the course of the disease necessary for the choice of the treatment strategy.

сахарный диабет 2-го типапостпрандиальная гликемиягликированный гемоглобинвариабельность глюкозыtype 2 diabetes mellituspoatprandial glycemiaglycated hemoglobinvariability of glucose levelReferencesАлгоритм специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой. 4-е изд., доп. М 2009;103.Алгоритм специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой. 4-е изд., доп. М 2009;103.Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabet Care 1997;20:1183-1197.Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabet Care 1997;20:1183-1197.International Diabetes Federation. Global guidelines for Type 2 diabetes. www.idf.org/home/index.cfmInternational Diabetes Federation. Global guidelines for Type 2 diabetes. www.idf.org/home/index.cfmAmerican Diabetes Association. Standards of Medical Care in diabetes-2010. Diabet Care 2010;33:Suppl 1:11-48.American Diabetes Association. Standards of Medical Care in diabetes-2010. Diabet Care 2010;33:Suppl 1:11-48.United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.Stettler C., Allemann S., Juni P. et al. Glycamic control and macrovascular disease in type 1 and 2 diabetes mellitus. Meta-analysis of randomized trials. Am Heart J 2006;152:1:27-38.Stettler C., Allemann S., Juni P. et al. Glycamic control and macrovascular disease in type 1 and 2 diabetes mellitus. Meta-analysis of randomized trials. Am Heart J 2006;152:1:27-38.UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140.UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140.Desousza L.C., Salazar H, Cheong B. et al. Association of Hypoglycemia and Cardiac Ischemia: A study based on continuous monitoring Diabet Care 2003;26:1485-1489.Desousza L.C., Salazar H, Cheong B. et al. Association of Hypoglycemia and Cardiac Ischemia: A study based on continuous monitoring Diabet Care 2003;26:1485-1489.Russell-Jones D., Khan R. Insulin-associated weight gain in diabetes - causes, effects and coping strategies. Diabet Obes Metab 2007;9:799-812.Russell-Jones D., Khan R. Insulin-associated weight gain in diabetes - causes, effects and coping strategies. Diabet Obes Metab 2007;9:799-812.Назаренко Г.И., Кишкун А.А. Клиническая оценка результатов лабораторных анализов. М: Медицина 2002;544.Назаренко Г.И., Кишкун А.А. Клиническая оценка результатов лабораторных анализов. М: Медицина 2002;544.Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein H.C., Miller M.E., Byington R.P. et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2459.Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein H.C., Miller M.E., Byington R.P. et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2459.ADVANCE Collaborative Group, Patel A., MacMahon S., Chalmers J. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.ADVANCE Collaborative Group, Patel A., MacMahon S., Chalmers J. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.The ADVANCE Collaborative Group. Action in Diabetes and Vascular disease: Preterax and Diamicron MR Controlled Evaluation. N Engl J Med 2008;358:2560-2572.The ADVANCE Collaborative Group. Action in Diabetes and Vascular disease: Preterax and Diamicron MR Controlled Evaluation. N Engl J Med 2008;358:2560-2572.Nathan D.M., Buse J.B., Davidson M.B. et al. American Diabetes Association, European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabeyes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and European Association for the Study of Diabetes. Diabet Care 2009;32:193-203.Nathan D.M., Buse J.B., Davidson M.B. et al. American Diabetes Association, European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabeyes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and European Association for the Study of Diabetes. Diabet Care 2009;32:193-203.Skyler S., Bergenstal R., Bonow R. et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Diabet Care 2009;32:1:187-192.Skyler S., Bergenstal R., Bonow R. et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Diabet Care 2009;32:1:187-192.Monnier L., Colette C., Dunseath C.J. et al. The Loss of Postprandial Clycemic control precedes stepwise deterioration of fasting with Worsening Diabetes. Care Diabet J 2007;30:263-269.Monnier L., Colette C., Dunseath C.J. et al. The Loss of Postprandial Clycemic control precedes stepwise deterioration of fasting with Worsening Diabetes. Care Diabet J 2007;30:263-269.β-клетка: секреция инсулина в норме и патологии. Под ред. И.И. Дедова. М 2005;31-41.β-клетка: секреция инсулина в норме и патологии. Под ред. И.И. Дедова. М 2005;31-41.Polonsky K.S., Gumbiner B., Ostrega D. et al. Alterations in immunoreactive proinsulin and insulin clearance induced by weight loss in NIDDM. Diabetes 1994;43:871-817.Polonsky K.S., Gumbiner B., Ostrega D. et al. Alterations in immunoreactive proinsulin and insulin clearance induced by weight loss in NIDDM. Diabetes 1994;43:871-817.Kawano H., Motoyama T., Hirashima O. et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999;34:1:146-154.Kawano H., Motoyama T., Hirashima O. et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999;34:1:146-154.Donahue R.P., Abbott R.D., Reed D.M. et al. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes 1987;36:689-692.Donahue R.P., Abbott R.D., Reed D.M. et al. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes 1987;36:689-692.The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-621.The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-621.Hanefeld M. , Fischer S, Julius U. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-1583.Hanefeld M. , Fischer S, Julius U. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-1583.Shichiri M., Kishikawa H., Ohkubo Y. et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetes patients. Diabet Care 2000;23:Suppl 2:B21-B29.Shichiri M., Kishikawa H., Ohkubo Y. et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetes patients. Diabet Care 2000;23:Suppl 2:B21-B29.Руководство по контролю постпрандиальной гликемии. International Diabetes Federation 2008.Руководство по контролю постпрандиальной гликемии. International Diabetes Federation 2008.Risso A., Mercuri F., Quagliaro L. et al. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 2001;281:5:E924-E930.Risso A., Mercuri F., Quagliaro L. et al. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 2001;281:5:E924-E930.Quagliaro L., Piconi L., Assaloni R. et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003;52:11:2795-2804.Quagliaro L., Piconi L., Assaloni R. et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003;52:11:2795-2804.Piconi L., Quagliaro L., Da R.R. et al. Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. J Thromb Haemost 2004;2:8:1453-1459.Piconi L., Quagliaro L., Da R.R. et al. Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. J Thromb Haemost 2004;2:8:1453-1459.Kupper A. Wintergers V. Association of Hypoglycemia, Hyperglycemia, and Glucose Variability With Morbidity and Death in the Pediatric Intensive Care Unit. Pediatrics 2006;118:173-179.Kupper A. Wintergers V. Association of Hypoglycemia, Hyperglycemia, and Glucose Variability With Morbidity and Death in the Pediatric Intensive Care Unit. Pediatrics 2006;118:173-179.Muggeo M. Fasting Plasma Glucose Variability Predicts 10-Year Survival of Type 2 Diabetes Patients: The Verona Diabetes Study. Diabet Care 2000;23:45-50.Muggeo M. Fasting Plasma Glucose Variability Predicts 10-Year Survival of Type 2 Diabetes Patients: The Verona Diabetes Study. Diabet Care 2000;23:45-50.

The authors declare that there are no conflicts of interest present.